Must Read

India adds record renewables capacity in past year

Country outstrips UK, Japan, France and Canada as renewable energy capacity soars India added 2.33GW of grid-connected renewable power capacity during the year to the end of March, according to a statement from the Ministry of New and Renewable Energy, mRead more

Cisco lifts lid on new partner marketing hub

Partner Demand Centre will serve as central hub for reseller marketing activity Cisco has created a new organisation tasked with boosting the speed and efficiency of partner marketing activities. The Cisco Partner Demand Centre will provide assistance toRead more

Crime agencies highlight dangers of online scams

Cybercrime awareness day warns internet users that online scams cost victims on average £325 each Cybercriminals cost the British public £3.5bn a year in frauds, scams and identity theft, according to the Serious Organised Crime Agency (Soca)....Read more

Ruckus asks Top Dogs to prove their pedigree

Vendor hires new UK supremo to back revamped partner programme Ruckus Wireless’ new UK chief is banking on the vendor’s first deal registration scheme and a fortified top-partner level to help grow its reseller base....Read more

Network provider calls on BT to reveal FTTC postcodes

Fibrestream boss wants Ofcom the put pressure on the telecoms giant Community network specialist Fibrestream has asked UK comms regulator Ofcom to force BT to provide the postcodes that will receive its fibre-to-the-cabinet (FTTC) connection....Read more

Breast Cancer Patients Often Confused by Genomic Testing (HealthDay)

MONDAY, March 8 (HealthDay News) -- Doctors need to do a better job of

explaining genomic test results to breast cancer patients, say U.S.

researchers.

Genomic testing -- which analyzes 21 genes in breast tumors removed

during surgery in order to predict the risk of cancer recurrence -- can

help guide decisions about the use of chemotherapy in patients with

early-stage breast cancer. Patients at high risk may decide on more

aggressive treatment, while those at low risk may opt to forego

chemotherapy and its potential side effects.

For this study, researchers surveyed 77 patients with early-stage,

estrogen receptor-positive breast cancer who underwent genomic testing

between 2004 and 2009.

About one-third of the women said they felt they did not fully

understand their discussions with doctors about their genomic test results

and their risk of cancer recurrence, and about one-quarter suffered

distress.

"Almost all women agreed that having the test gave them a better

understanding of their treatment options chance of success," Noel Brewer,

an assistant professor of health behavior and health education at the

University of North Carolina's Gillings School of Public Health, said in a

news release. "Most women said that they would have the test if they had

to decide again today, and that they would recommend the test to other

women in their same situation."

The researchers also found that most women accurately remembered the

risk results from their genomic test.

While most patients in the study had a positive attitude about genomic

testing and felt that it helped them better understand their treatment

options, there is room for improvement in how doctors discuss cancer

recurrence risk and treatment decisions with patients, Brewer and

colleagues concluded.

The study is published online March 8 in the journal Cancer.

More information

The American Association for Clinical Chemistry has more about breast cancer testing.

Taken from here

Breast Cancer Patients Often Confused by Genomic Testing (HealthDay)

Arts & Entertainment

Business & Economy

Computers & Internet

Health & Sports

Shopping

Kids